Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Orismilast (LEO 32731) in healthy volunteers
NCT02514694Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Jul 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Psoriasis vulgaris (PV) comparing LEO 32731 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events at 16 days. Started Jul 2015; status: completed.
02
Drugs
orismilast
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT02514694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514694.